Glafenine

General information

Glafenine, an anthranilic acid derivative, has been withdrawn in much of the world [ ]. Until 1991 it was sold in about 70 countries (although never marketed or accepted in others), despite a long history of severe reactions (particularly anaphylaxis, fatal hepatotoxicity, and nephrotoxicity, even with normal doses). As late as 1989 the EC Committee on Proprietary Medicinal Products (CPMP) astonishingly recommended keeping glafenine on the market but controlling its distribution and monitoring adverse reactions more closely [ ]. Firm restrictions or prohibitions nevertheless preceded or followed this recommendation in several European countries, and the CPMP finally condemned glafenine early in 1992.

Organs and systems